477 EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. REAL-LIFE EVIDENCE FROM ENEIDA REGISTRY. | Publicación